Business- Page 75

BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notified Nurix of its decision

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved

Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms

Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is

PITTSBURGH, Nov. 03, 2026 (GLOBE NEWSWIRE) — Duolingo, Inc. (NASDAQ: DUOL) announced results for the third quarter ended September 30, 2026 in a shareholder letter that is posted on its Investor Relations

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four

ATLANTA, Nov. 03, 2026 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to

Creates a Full-Stack RF Front-End Platform for Next-Generation Smartphones Expands Reach Across Four Secular Growth Markets – Physical AI, Defense, Infrastructure, and Automotive Broadens Technology Portfolio with RF GaN, Low-Voltage Power and

Net Investment Income of $0.33 Per Share for Q3 2026; Declared Quarterly Distribution of $0.31 Per Share NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — SLR Investment Corp. (NASDAQ: SLRC) (the “Company”,